Breadcrumb Home investors intimation stock exchanges Intimation to stock Exchanges Quick Explore Corporate Governance Shareholding Pattern Investor contact Year 2026-20272025-20262024-20252023-20242022-20232021-20222020-20212019-20202018-20192017-20182016-20172015-20162014-20152013-20142012-20132011-20122010-2011 Apply Schedule of Analyst Institutional Investor Meeting 11th Jan 2022 Issuance of duplicate share certificates 06th Jan 2022 Board Meeting Intimation - Jan 2022 30th Dec 2021 Corrigendum to Press Release - Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu® (Molnupiravir 200 mg) in India to treat mild to moderate COVID-19 at high risk of developing severe disease 28th Dec 2021 Press Release - Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu® (Molnupiravir 200 mg) in India to treat mild to moderate COVID-19 at high risk of developing severe disease 28th Dec 2021 Schedule of Analyst Institutional Investor Meeting 22nd Dec 2021 Press Release - Cipla Receives Final Approval for Lanreotide Injection 18th Dec 2021 Allotment of 3,375 equity shares under ESOS 2013-A 17th Dec 2021 Schedule of Analyst Institutional Investor Meeting 17th Dec 2021 Press Release - Cipla acquires stake in Clean Max Auriga Power LLP “progresses towards championing its ESG agenda” 15th Dec 2021 Pagination First page first Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Next page › Last page last BSE and NSE Quotes by TradingView The displayed data is not in real time and may have streaming delays.
